PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11724337-0	2001	9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.	9-hydroxyellipticine	0-20	tumor protein p53	Homo sapiens	88-91
15548707-6	2004	On the basis of this analysis, formation of 9-hydroxyellipticine and 7-hydroxyellipticine was attributable to CYP1A1/2, whereas production of 13-hydroxyellipticine and ellipticine N(2)-oxide, the metabolites responsible for formation of two major DNA adducts, was attributable to CYP3A4.	9-hydroxyellipticine	44-64	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	110-118
15548707-7	2004	Using recombinant human enzymes, oxidation of ellipticine to 9-hydroxyellipticine and 7-hydroxyellipticine by CYP1A1/2 and to 13-hydroxyellipticine and N(2)-oxide by CYP3A4 was corroborated.	9-hydroxyellipticine	61-81	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	110-118
12570841-1	2003	The hydroxy group in 9-hydroxyellipticines increases the apparent affinity for DNA, stabilisation of toposiomerase II-DNA cleavable complex, oxidation to reactive quinone-imine intermediates, phosphorylation of p53 suppressor proteins and cytotoxicity relative to the parent ellipticines.	9-hydroxyellipticine	21-42	tumor protein p53	Homo sapiens	211-214
23293027-5	2013	Here we report that a number of the ellipticines, including 9-hydroxyellipticine, are potent and specific inhibitors of Pol-I transcription, with IC(50) in vitro and in cells in the nanomolar range.	9-hydroxyellipticine	60-80	DNA polymerase iota	Homo sapiens	120-125
17159771-8	2006	Using the reconstituted enzymatic system, we demonstrated that the detoxication ellipticine metabolites, 7-hydroxyellipticine and 9-hydroxyellipticine, are mainly generated by CYP1A1 and 1A2, while those responsible for DNA binding, 13-hydroxy-, 12-hydroxyellipticine and ellipticine N(2)-oxide, by CYP3A1 and 2C3.	9-hydroxyellipticine	130-150	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	176-190
11724337-3	2001	We examined whether 9-hydroxyellipticine (9HE), a cytotoxic agent, affected the tertiary structure of mutant p53 and DNA binding characteristics.	9-hydroxyellipticine	20-40	tumor protein p53	Homo sapiens	109-112
11724337-3	2001	We examined whether 9-hydroxyellipticine (9HE), a cytotoxic agent, affected the tertiary structure of mutant p53 and DNA binding characteristics.	9-hydroxyellipticine	42-45	tumor protein p53	Homo sapiens	109-112
3729973-8	1986	The cytochrome P-450c inhibitor 9-hydroxyellipticine inhibited conversion of pentachlorophenol to tetrachlorobenzenediols by HCB and beta-naphthoflavone induced micromes.	9-hydroxyellipticine	32-52	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	4-21
9883907-2	1998	We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor alkaloid, would inhibit telomerase activity because the drug has a unique mechanism of inhibiting phosphorylation of mutant p53 protein via inhibition of protein kinases, thereby restoring wild-type p53 function.	9-hydroxyellipticine	21-41	tumor protein p53	Homo sapiens	187-190
9883907-2	1998	We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor alkaloid, would inhibit telomerase activity because the drug has a unique mechanism of inhibiting phosphorylation of mutant p53 protein via inhibition of protein kinases, thereby restoring wild-type p53 function.	9-hydroxyellipticine	21-41	tumor protein p53	Homo sapiens	262-265
9883907-2	1998	We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor alkaloid, would inhibit telomerase activity because the drug has a unique mechanism of inhibiting phosphorylation of mutant p53 protein via inhibition of protein kinases, thereby restoring wild-type p53 function.	9-hydroxyellipticine	43-47	tumor protein p53	Homo sapiens	187-190
9883907-2	1998	We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor alkaloid, would inhibit telomerase activity because the drug has a unique mechanism of inhibiting phosphorylation of mutant p53 protein via inhibition of protein kinases, thereby restoring wild-type p53 function.	9-hydroxyellipticine	43-47	tumor protein p53	Homo sapiens	262-265
9883907-5	1998	We conclude that 9-HE may exert a strong inhibitory effect on telomerase activity possibly through inhibition of protein kinases rather than through restoration of functional wild-type p53.	9-hydroxyellipticine	17-21	tumor protein p53	Homo sapiens	185-188
8975635-9	1996	Inhibition of EROD and PROD by 9-hydroxyellipticine, a specific inhibitor of rat hepatic cytochrome P4501A1, revealed that PROD induction by TCDD and other P4501A-inducers was probably a result of a broader substrate specificity of chick embryo P4501A.	9-hydroxyellipticine	31-51	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	89-107
7591958-0	1995	Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism.	9-hydroxyellipticine	45-65	tumor protein p53	Homo sapiens	14-17
7591958-2	1995	We found that ellipticine and 9-hydroxyellipticine (9HE), antitumor alkaloids, caused selective inhibition of p53 protein phosphorylation in Lewis lung carcinoma and SW480 (human colon cancer cell line) in a concentration-dependent manner from 0.1 to 100 microM.	9-hydroxyellipticine	30-50	tumor protein p53	Homo sapiens	110-113
7591958-2	1995	We found that ellipticine and 9-hydroxyellipticine (9HE), antitumor alkaloids, caused selective inhibition of p53 protein phosphorylation in Lewis lung carcinoma and SW480 (human colon cancer cell line) in a concentration-dependent manner from 0.1 to 100 microM.	9-hydroxyellipticine	52-55	tumor protein p53	Homo sapiens	110-113
10737712-0	2000	Diverse effects of 9-hydroxyellipticine on the chemosensitivity of human pancreatic cancer cells harboring p53 mutations.	9-hydroxyellipticine	19-39	tumor protein p53	Homo sapiens	107-110
10737712-1	2000	Recently, it has been shown that 9-hydroxyellipticine (9-HE), an antitumor alkaloid has a unique property of restoring functional wild-type (wt) p53 activity via inhibition of mutant (mt) p53 protein phosphorylation.	9-hydroxyellipticine	33-53	tumor protein p53	Homo sapiens	145-148
10737712-1	2000	Recently, it has been shown that 9-hydroxyellipticine (9-HE), an antitumor alkaloid has a unique property of restoring functional wild-type (wt) p53 activity via inhibition of mutant (mt) p53 protein phosphorylation.	9-hydroxyellipticine	33-53	tumor protein p53	Homo sapiens	188-191
10737712-1	2000	Recently, it has been shown that 9-hydroxyellipticine (9-HE), an antitumor alkaloid has a unique property of restoring functional wild-type (wt) p53 activity via inhibition of mutant (mt) p53 protein phosphorylation.	9-hydroxyellipticine	55-59	tumor protein p53	Homo sapiens	145-148
10737712-1	2000	Recently, it has been shown that 9-hydroxyellipticine (9-HE), an antitumor alkaloid has a unique property of restoring functional wild-type (wt) p53 activity via inhibition of mutant (mt) p53 protein phosphorylation.	9-hydroxyellipticine	55-59	tumor protein p53	Homo sapiens	188-191
10737712-3	2000	Exposure of cells to 9-HE at a relatively low concentration of 1 microM induced almost no cell death but was sufficient to restore wt p53 activity, as evidenced by an induction of endogenous p21WAF1/CIP1 concomitant with G1 and G2/M arrests in cell-cycle progression.	9-hydroxyellipticine	21-25	tumor protein p53	Homo sapiens	134-137
10737712-6	2000	These effects of 9-HE were specific for several cell lines containing mt p53 and were not observed in p53-negative or wt p53 expressing cells.	9-hydroxyellipticine	17-21	tumor protein p53	Homo sapiens	73-76
10652599-0	1999	Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine.	9-hydroxyellipticine	80-100	tumor protein p53	Homo sapiens	7-10
10652599-2	1999	Although in many cancer cells p53 is frequently mutated and loses its functions, we have proposed that mutant p53 may be involved in the anticancer mechanism of 9-hydroxy ellipticine (9HE).	9-hydroxyellipticine	161-182	tumor protein p53	Homo sapiens	30-33
10652599-2	1999	Although in many cancer cells p53 is frequently mutated and loses its functions, we have proposed that mutant p53 may be involved in the anticancer mechanism of 9-hydroxy ellipticine (9HE).	9-hydroxyellipticine	161-182	tumor protein p53	Homo sapiens	110-113
10652599-2	1999	Although in many cancer cells p53 is frequently mutated and loses its functions, we have proposed that mutant p53 may be involved in the anticancer mechanism of 9-hydroxy ellipticine (9HE).	9-hydroxyellipticine	184-187	tumor protein p53	Homo sapiens	30-33
10652599-2	1999	Although in many cancer cells p53 is frequently mutated and loses its functions, we have proposed that mutant p53 may be involved in the anticancer mechanism of 9-hydroxy ellipticine (9HE).	9-hydroxyellipticine	184-187	tumor protein p53	Homo sapiens	110-113
8240392-2	1993	9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes.	9-hydroxyellipticine	0-21	aryl hydrocarbon receptor	Rattus norvegicus	107-137
8240392-2	1993	9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes.	9-hydroxyellipticine	0-21	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	173-201
8240392-2	1993	9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes.	9-hydroxyellipticine	0-21	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	212-215
8240392-2	1993	9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes.	9-hydroxyellipticine	23-28	aryl hydrocarbon receptor	Rattus norvegicus	107-137
8240392-2	1993	9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes.	9-hydroxyellipticine	23-28	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	173-201
8240392-2	1993	9-Hydroxy ellipticine (9-OHE), a metabolite of the anti-neoplastic agent ellipticine, is known to bind the aryl hydrocarbon (Ah) receptor in rat lung cytosol and to inhibit aryl hydrocarbon hydroxylase activity (AHH) in rat hepatic microsomes.	9-hydroxyellipticine	23-28	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	212-215
8240392-3	1993	In this study, the effects of 9-OHE on the transformation of the rat hepatic cytosolic Ah receptor to a form that binds the xenobiotic responsive enhancer element-3 (XRE-3) of the cytochrome P4501A1 gene was investigated.	9-hydroxyellipticine	30-35	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	180-198
1420465-2	1992	The reactions, which involve the formation of 9-oxo-ellipticine and the addition of a nucleophilic acid on the C10 site of the heterocyclic system, have been used to measure 9-OH-E quantitatively by colorimetry in solution and by reflection on paper surfaces.	9-hydroxyellipticine	174-180	homeobox C10	Homo sapiens	111-114
6692492-0	1984	Induction by 9-hydroxyellipticine of aryl hydrocarbon hydroxylase in perinatal rat liver and in primary fetal hepatocytes in culture.	9-hydroxyellipticine	13-33	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	37-65
6087804-2	1984	Purified cytochrome P-448 (LM4), but not cytochrome P-450 (LM2), catalysed the O-de-ethylation of ethoxyresorufin in a reaction that was markedly inhibited by 9-hydroxyellipticine.	9-hydroxyellipticine	159-179	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	9-25
3996731-2	1985	An excellent direct correlation (r = 0.95) has been observed between ethoxyresorufin O-deethylase and the metabolic activation of benzo[a]pyrene to mutagens when the fraction of cytochromes P-450 present as cytochrome P-448 was altered by the administration of phenobarbitone and 3-methylcholanthrene alone or in combination with 9-hydroxyellipticine.	9-hydroxyellipticine	330-350	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	207-223
6692492-1	1984	In neonatal and, to a lesser extent, in fetal rat liver, 9-hydroxyellipticine was able to promote the induction of cytochrome P-450, supporting especially aryl hydrocarbon hydroxylase (AHH) but not aldrin epoxidase activity.	9-hydroxyellipticine	57-77	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	115-131
6692492-1	1984	In neonatal and, to a lesser extent, in fetal rat liver, 9-hydroxyellipticine was able to promote the induction of cytochrome P-450, supporting especially aryl hydrocarbon hydroxylase (AHH) but not aldrin epoxidase activity.	9-hydroxyellipticine	57-77	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	155-183
6692492-1	1984	In neonatal and, to a lesser extent, in fetal rat liver, 9-hydroxyellipticine was able to promote the induction of cytochrome P-450, supporting especially aryl hydrocarbon hydroxylase (AHH) but not aldrin epoxidase activity.	9-hydroxyellipticine	57-77	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	185-188
7181861-2	1982	The two forms of the cytochrome have different substrate specificities; cytochrome P-450 has one type 1 substrate-binding site that can accommodate a large variety of substrates, but in contrast cytochrome P-448 may possess two type 1 substrate-binding sites, one of which is different to that of cytochrome P-450 in that it shows a specificity for substrates such as safrole and 9-hydroxy-ellipticine.	9-hydroxyellipticine	380-401	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	72-88
7151231-2	1982	Biphenyl displaced the 9-hydroxyellipticine ligand from cytochrome P-448 leading to increased free cytochrome, but with no corresponding increase in mixed-function oxidase activity when biphenyl was used as substrate.	9-hydroxyellipticine	23-43	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	56-72
7151231-4	1982	Administration of 9-hydroxyellipticine to safrole-pretreated rats inhibited the cytochrome P-448-catalysed activity, but had no effect on the cytochrome P-450-catalysed activity.	9-hydroxyellipticine	18-38	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	80-96
7151231-6	1982	The type I substrate biphenyl displaced both the safrole carbene and the 9-hydroxyellipticine ligands from cytochrome P-448 resulting in increased free cytochrome.	9-hydroxyellipticine	73-93	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	107-123
7285236-3	1981	9-Hydroxyellipticine (9-OHE) interacts with human liver cytochrome P-450 exhibiting a type II spectrum (lambda max: 428 nm, Ks = 1.1 microM).	9-hydroxyellipticine	0-20	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
7172416-0	1982	The mutagenicity of 9-hydroxyellipticine and its induction of cytochrome P-448 activity in rat liver microsomes.	9-hydroxyellipticine	20-40	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	62-78
7172416-1	1982	Administration of a single dose of the inhibitor of the hepatic mixed function oxidases, 9-hydroxyellipticine (9-OHE), resulted in a marked increase in the cytochrome P-448 catalysed activities of ethoxyresorufin O-deethylase, biphenyl 2-hydroxylase and activation of benzo[a]pyrene to mutagens.	9-hydroxyellipticine	89-109	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	156-172
7172416-1	1982	Administration of a single dose of the inhibitor of the hepatic mixed function oxidases, 9-hydroxyellipticine (9-OHE), resulted in a marked increase in the cytochrome P-448 catalysed activities of ethoxyresorufin O-deethylase, biphenyl 2-hydroxylase and activation of benzo[a]pyrene to mutagens.	9-hydroxyellipticine	111-116	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	156-172
7172416-4	1982	It is concluded that 9-OHE may also act as an inducer of the hepatic microsomal mixed function oxidases, selectively inducing the synthesis of cytochrome P-448.	9-hydroxyellipticine	21-26	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	143-159
7285236-3	1981	9-Hydroxyellipticine (9-OHE) interacts with human liver cytochrome P-450 exhibiting a type II spectrum (lambda max: 428 nm, Ks = 1.1 microM).	9-hydroxyellipticine	22-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-72
7428105-0	1980	Inhibition of cytochrome P-448 mixed function oxidase activity following administration of 9-hydroxyellipticine to rats.	9-hydroxyellipticine	91-111	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	14-30
7428105-3	1980	Following the pretreatment of rats intraperitoneally with 9-hydroxyellipticine and phenobarbitone, the cytochrome P-448-specific enzyme activity, ethoxyresorufin O-deethylase, was 50% inhibited in vitro but cytochrome P-450, cytochrome P-450 reductase, and other mixed function oxidase activities were unaffected.	9-hydroxyellipticine	58-78	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	103-119
7428105-1	1980	The in vitro inhibitor of mixed-function oxidation, 9-hydroxyellipticine, non-competitively inhibited the binding of the type II substrate, aniline, to cytochrome P-448 of hepatic microsomal preparations from rats pretreated with 3-methylcholanthrene.	9-hydroxyellipticine	52-72	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	152-168
7428105-3	1980	Following the pretreatment of rats intraperitoneally with 9-hydroxyellipticine and phenobarbitone, the cytochrome P-448-specific enzyme activity, ethoxyresorufin O-deethylase, was 50% inhibited in vitro but cytochrome P-450, cytochrome P-450 reductase, and other mixed function oxidase activities were unaffected.	9-hydroxyellipticine	58-78	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	207-251
7428105-4	1980	With rats pretreated with 9-hydroxyellipticine and 3-methylcholanthrene, inhibition of ethoxyresorufin O-deethylase was 90%, and cytochrome P-450/P-448, cytochrome P-450 reductase, biphenyl 2- and 4-hydroxylase were inhibited by 30, 15, 50 and 40% respectively.	9-hydroxyellipticine	26-46	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	129-145
7428105-4	1980	With rats pretreated with 9-hydroxyellipticine and 3-methylcholanthrene, inhibition of ethoxyresorufin O-deethylase was 90%, and cytochrome P-450/P-448, cytochrome P-450 reductase, biphenyl 2- and 4-hydroxylase were inhibited by 30, 15, 50 and 40% respectively.	9-hydroxyellipticine	26-46	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	153-169
7428105-5	1980	It is concluded that 9-hydroxyellipticine administered in vivo markedly inhibits mixed-function oxidations which are specific to cytochrome P-448, but has no effect on cytochrome P-450-catalysed microsomal oxidation.	9-hydroxyellipticine	21-41	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	129-145
498356-0	1979	Interaction of 9-hydroxyellipticine with two forms of partially purified rabbit lung cytochrome P-450.	9-hydroxyellipticine	15-35	cytochrome P-450	Oryctolagus cuniculus	85-101